In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
CAR T-cell therapy equips a patient’s T cells to recognize a specific tumor target, but that fixed recognition can become a limitation when cancer cells express different antigens or lose the target the therapy was designed to attack. A preclinical platform developed at City of Hope explores whether engineered T cells could be redirected after infusion—allowing clinicians to broaden tumor recognition without manufacturing an entirely new CAR T-cell product.
